


Anterior and Posterior Segment Case Presentations
Enough Pearls to Make a Necklace

Greg Caldwell, OD, FAAO
South Dakota Optometric Society
September 18, 20/20


Disclosure Statement
(next slide)



1

Disclosures- Greg Caldwell, OD, FAAO

- ~ Will mention many products, instruments and companies during our discussion
 - * I don't have any financial interest in any of these products, instruments or companies
- ~ Pennsylvania Optometric Association - President 2010
 - POA Board of Directors 2006-2011
- ~ American Optometric Association, Trustee 2013-2016
- ~ I never used or will use my volunteer positions to further my lecturing career
- ~ Lectured for: Shire, BioTissue, Optovue, Alcon, Allergan, Aerie
- ~ Advisory Board: Allergan, Sun
- ~ Envolve: PA Medical Director, Credential Committee
- ~ TelaSight: Consultant
- ~ TelaHealth: Ambassador
- ~ Optometric Education Consultants - Scottsdale, WDW, St. Paul, Quebec City, and Nashville, Owner



2

Learning Objectives

- ~ Emphasize clinical diagnosis of anterior and posterior segment disease.
- ~ Strengthen clinical treatment of anterior and posterior segment disease.
- ~ Heighten the clinician's comfort level when treating disease with topical and/or oral medications.
- ~ Gain confidence in ordering and interpreting diagnostic and laboratory tests.
- ~ Gain confidence in making a subspecialty referral

3

Optometric Public Service Announcement
Pay Very Close Attention


4

80-year-old man

- ~ Reports a sudden loss of vision OD
- ~ Vision is count fingers at 2 feet OD and 20/25 OS
- ~ APD OD grade 4
- ~ Fundus photos OU


5

Photos OU



6

CRAO Treatment/Work-Up/Follow-Up?




Anterior chamber paracentesis (less than 24 hours)

STAT blood work

- * 2-10% of all CRAOs are caused by thrombosis from Giant Cell Arteritis (GCA)
- * Sed-rate
- * C-reactive protein
 - Qualitative or quantitative?
- * CBC with diff

Monitor for neovascularization, every 3-6 weeks



7

CRAO, BRAO, TIA (amaurosis fugax)

Acute Stroke Ready Hospital

- Certification recognizes hospitals that meet standards to support better outcomes for stroke care as part of a stroke system of care
- Developed in collaboration with the Joint Commission (JCI), eligibility standards include
- Dedicated stroke focused program
- Staffing by qualified medical professionals trained in stroke care
- Relationship with local emergency management systems (EMS) that encourages training in field assessment tools and communication with the hospital prior to bringing a patient with a stroke to the emergency department
- Access to stroke expertise 24 hours a day, 7 days a week (in person or via telemedicine) and transfer agreements with facilities that provide primary or comprehensive stroke services
- 24/7 ability to perform rapid diagnostic imaging and laboratory testing to facilitate the administration for IV thrombolysis in eligible patients
- Streamlined flow of patient information while protecting patient rights, security and privacy
- Use of data to assess and continually improve quality of care for stroke patients

Warn hospital if suspicion for GCA


- 20% of stroke or heart attack within 3 years
- However of those who experienced CVA or MI
 - 80% were within 24-48 hours; those remaining
 - 50% occurred in 2 weeks
 - Majority within the next 90 days

Not PCP, not retinologist, just the Acute Stroke Ready Hospital!

8

Acute Stroke Ready Hospital

- Is the basic level stroke hospital, better than not certified
 - * This was created in 2015
- If you have access to a: (Even Better)
 - * Primary Stroke Center
 - * Thrombectomy-Capable Stroke Center
 - * Comprehensive Stroke Center even better



9




10



11


April 8, 2020 - COVID 19




12



13



14



15

25-year-old man

- ~ Patient has been to 3 ophthalmologists and 1 optometrist in the past year
- ~ Patient complains of a “ghost image” OS
- ~ Has had 4 dilated exams in past year, and no diagnosis yet
- ~ He is very passionate that his vision is clear OD and “ghosty” OS
 - * He wants to know why

16

“Ghost Image” OS

Va 20 / 20	Current Correction
cc 20	R -2.50-1.00 x 180
	L -3.25-1.00 x 180

EOMS: full, unrestricted	PERRL (-)APD
CT: ortho D/N	CF: full by FC OU


~ SLE-unremarkable	~ Previous unremarkable tests
~ Fundus-unremarkable	* Topography
	* Fluorescein angiography
	* CAT scan
	* MRI

17

Any Thoughts About “Ghost Images”?

- ~ Previous unremarkable tests
 - * Topography
 - * Fluorescein angiography
 - * CAT scan
 - * MRI

18



19

How I felt when I finally realized keratoconus starts posteriorly

A cartoon character with a large head, wide eyes, and a big smile, jumping with its arms raised in the air. The character is wearing a simple suit and shoes.

20

Forme Fruste Keratoconus

- ⌘ Treatment
- ⌘ RGP lens in office and trial frame over refraction
 - * Eliminated "ghost image"
- ⌘ Patient currently only in spex
 - * Not interested in RGP lens
- ⌘ RTC 1 year, BVA and topographies

21


Case 2

22


Advanced Keratoconus

Four grayscale photographs of eyes, arranged in a 2x2 grid. The top two images show the eyes from a slightly elevated angle, and the bottom two show them from a lower angle. The corneas appear distorted and irregular, characteristic of advanced keratoconus.


23



24



25



26

Keratoconus

Progressive corneal disease

- * Focal thinning, steepening, bulging, and irregular shape
- * Loss of biomechanical strength
- * Bilateral, asymmetric, clinically non-inflammatory

Caused by a combination of genetic and environmental factors

- * Allergies and eye rubbing

Onset in puberty


- * Typically progressive to 4th decade of life
- * Previously estimated 1:2000 (1986 US), more recent estimate 1:375 (2017 Netherlands)

Normal

KC

Photo courtesy of Dr. Steve Galvin, O.D., of CCR

28



29

Importance of Early Diagnosis in Keratoconus

- As keratoconus progresses, it becomes more challenging to manage
- Progressive keratoconus often results in:
 - Loss of visual acuity
 - Decreased tolerance to contact lens wear, caused by the ongoing changes in the cornea
- The earlier progressive keratoconus is diagnosed, the sooner treatment can be provided that may slow the progression of the disease.¹
- **Important to diagnose and educate patients before visual function is lost**
- CXL is an early intervention intended to slow or halt the progression of keratoconus

1. Gelles, J. D., OD, FAO, FCLSA. (2017, April). The Optometrist's Role in Keratoconus Management. Advanced Ocular Care.

30

LOOK OUT FOR KC!


Watch Out for Keratoconus! Potential Signs & Symptoms

- ▶ **Look out** for warning signs in medical history
 - History of eye rubbing
 - Family & genetic predispositions
- ▶ **Look out** for visual complaints
 - Blurred vision
 - Distortion of images
- ▶ **Look out** for refractive anomalies
 - Distortion of mires on keratometry
 - Error messages on autorefractors
 - Unsatisfactory attempts at vision correction & progressive loss of UCVA & BCVA
 - Increasing astigmatism


31

Cross-linking Procedure Summary


1. Remove epithelium



2. Soak cornea Photrea® Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) for 30 minutes



3. Check for flare



4. Once flare is observed, measure corneal thickness


If corneal thickness is less than 400 um, instill 2 drops of Photrea (riboflavin 5'-phosphate in ophthalmic solution) until the corneal thickness increases to at least 400 um

5. Irradiate for 30 minutes

Continue applying Photrea Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) during irradiation.

* Refer to prescribing information for entire FDA-approved procedure

32



33

Case 3

34

28-year-old man

- ~ Had LASIK 14 months ago
- ~ His right eye is now very blurry
- ~ He tried calling for an appointment the center is now closed


35

Va 20 / 40 Current Correction
 cc / 20 R +0.50-7.00 x 040
 L -0.25 sphere

EOMS: full, unrestricted PERRL (-)APD
 CT: ortho D/N CF: full by FC OU

- ~ SLE-trace fibrosis at flap edges, no stain
- ~ SLE-few multi-directional striae OD>OS
- ~ SLE-clean interface OU
- ~ Fundus-unremarkable


36




graphy
3D

- ~ Diagnosis:
 - Keratectasia 2° LASIK
- ~ RGP OD 20/20-2
 - This lasted for about 3 months
 - Multiple RGPs later due to progression of astigmatism to 8.5 D (BVA 20/50-2)
 - Finally PKP was done Jan 2006


37



38




39




40



41



42



43


Treatment Options

(Once Abrasion Resolved, to Help Prevent Recurrence)

When is it time for surgical procedure?


Answer: medical treatment failure

- Medical
 - Hypertonic
 - Gts
 - Ung
 - Bandage contact lens
 - Notalam
 - Doxycycline/Minocycline
 - Amniotic membrane (PROKERA™)
- Surgical/Procedures
 - Anterior stromal micropuncture
 - Debridement
 - Chemically
 - Mechanically
 - Beaver blade/diamond burr
 - Excimer phototherapeutic keratectomy (PTK)



44


The Basics of Amniotic Membrane



45


The Amniotic Membrane

- The amniotic membrane is the innermost lining of the placenta (amnion)
- Amniotic membrane shares the same cell origin as the fetus
 - Stem cell behavior
- Structural similarity to all human tissue




46

The CRYOTEK™ Method



- Patented and proprietary cryopreservation
- Ensures key active components of the **Extracellular Matrix (ECM)** are retained
- The **only** method that retains both:
 - The integrity of the tissue structure
 - The key active (ECM) components
- Safe and effective
 - Supported by over **300** peer-reviewed articles
 - Over **100,000** implanted
- Bio-Tissue Cryopreserved Amniotic Membrane is the **ONLY** AM granted wound healing indication by the FDA.



47

Technology Highlights

Impressive regenerative **platform** that possesses natural growth factors and optimal scaffolding properties within a complex extracellular matrix that are:

- Anti-inflammatory
- Anti-scarring
- Anti-angiogenic

Therapeutic actions:

- Promotes Stem Cell Expansion
- Suppresses pain
- Promotes cellular migration
- Expedites recovery



48

PROKERA®: BIOLOGIC CORNEAL BANDAGE

- PROKERA® utilizes the proprietary CryoTek™ cryopreservation process that maintains the active extracellular matrix of the amniotic membrane which uniquely allows for regenerative healing.
- PROKERA® is the only FDA-cleared therapeutic device that both reduces inflammation and promotes scar less healing
- PROKERA® can be used for a wide number of ocular surface diseases with severity ranging from mild, moderate, to severe



49


PROKERA®: Biologic Corneal Bandage An Active Amniotic Membrane

PROKERA 1000	PROKERA	PROKERA 2000
Mild to Moderate	Moderate to Severe	Severe
<ul style="list-style-type: none"> • (Microbial, HSV) • Recurrent Corneal Erosions • Corneal Abrasions / Wounds 	<ul style="list-style-type: none"> • Neurotrophic PED • Severe Infectious Keratitis • Post DSEK for Bullous Keratopathy • Corneal Wounds 	<ul style="list-style-type: none"> • Chemical Burns • Stevens Johnson Syndrome • Severe Corneal Ulcers • Corneal Wounds

50

Excimer Phototherapeutic Keratectomy (PTK)

- ⌘ Corneal Opacities
 - * Scarring
 - * Granular dystrophy
- ⌘ Surface Irregularity
 - * Saltzman nodules
- ⌘ Surface Breakdown
 - * Epithelial basement membrane dystrophy




51

PTK Procedure

- ⌘ Removal of epithelium
- ⌘ Manual debridement
- ⌘ Polish with excimer


52

PRK



53

PTK



54


Post op Regimen

- ⌘ Vigamox and Pred-Forte q2°
 - * Until wound is closed
- ⌘ Bandage contact lens (BCL)
- ⌘ Vitamin C, 1000 mg/day x 1 month
- ⌘ NP-artificial tears
- ⌘ Sunglasses in any UV

55




56



57




58




59




60




61




62




63




64



65



66



67

Differential Diagnosis

- Hypertensive retinopathy
- Blood dyscrasia
- Terson's syndrome
- Valsalva retinopathy
- Purtscher's retinopathy
- Shaken baby syndrome

68

Terson's Syndrome

- Terson's syndrome originally was defined by the occurrence of vitreous hemorrhage in association with subarachnoid hemorrhage
- Terson's syndrome now encompasses any intraocular hemorrhage associated with intracranial hemorrhage and elevated intracranial pressures
- Intraocular hemorrhage includes the development of subretinal, retinal, sub-hyaloidal, or vitreal blood
- The classic presentation is in the sub-hyaloidal space

69

Treatment

- Emergency referral to neurologist due to high suspicion of intracranial hemorrhage and elevated intracranial pressure
- Intracranial hemorrhage confirmed with MRI
- Patient later diagnosed with Hairy Cell Leukemia and cryptococcal meningitis

70

Case 7

71

8-year-old girl

- Mom noticed the left eyelid has become red and has pimples
- Started two days ago
- Slowly getting more pimples on the eyelid
- Globe not affected

72

Slit Lamp Evaluation



- Diagnosis
 - Herpes simplex blepharitis
- Treatment
 - 400 mg Acyclovir 5x/day
 - Call to pediatrician



73

Case 8


74

58-year-old woman

- ~ VA OD 20/200 OS 20/400
- ~ Longstanding history of macular degeneration
- ~ Anything suspicious here?
 - *?? Longstanding AMD in 58-year-old??
- ~ History of cataract surgery OU
- ~ Glasses Rx OD -1.00 OS -1.00

75

Axial length 29.85 mm



OD -18.00 OS -18.50 prior to cataract surgery

76



At what diopter value is a patient considered a degenerative or pathological myope?

77

Degenerative Myopia

- ~ Differs from refractive myopia
 - * There is an alteration of globe structure that is progressive
 - * Primary alteration is a posterior elongation of eyeball as a result of progressive thinning of sclera
 - Posterior staphyloma

78

Degenerative Myopia

- ~ Findings
 - * Lacquer cracks
 - * Posterior staphyloma
 - * Fuch's spot
 - * RPE and choroidal atrophy
 - * Scleral crescents
 - * Vessel straightening
 - * Disc tilting
 - * Peripheral retinal changes
- } Can be found in refractive and degenerative myopes

79

Conditions Associated With Degenerative Myopia

- ☞ Fetal Alcohol Syndrome
- ☞ Ocular albinism
- ☞ Down's Syndrome
- ☞ Low birth weight
- ☞ Infantile glaucoma
- ☞ Retinopathy of Prematurity
- ☞ Marfan's Syndrome

80

Treatment

- ☞ BVA with glasses/contact lenses
- ☞ Education regarding trauma and possible eye hazards
- ☞ Monitor for neovascularization and peripheral retinal changes
- ☞ Follow-up at least yearly


81

Which patient is at higher risk of retinal detachment?



Two patients are in your office
 -8.00 D refractive myope
 -14.00 D degenerative myope

82




83

Clinical Pearl


- ☞ Refractive myopia
 - * Peripheral retina is general concern
- ☞ Degenerative/Pathological myopia
 - * Posterior pole is general concern
 - ☐ Posterior staphyloma

84


Peripheral Fundus Findings




85




86




87




88



89



90



91



92

Clinical Pearl
Is there a difference between
Geographic Atrophy and Disciform Scar

93


Case 10

94

65-year-old woman

- Referred by an optometrist due to corneal edema and map-like anterior opacities
 - Impression is EBMD versus corneal degeneration
- Patient reports decreasing vision over past 6-9 months
 - Especially at near
- Vision 20/50 OU

95




96


Patient's Medications

- Baby ASA
- Lanoxin
- Synthroid
- Glucophage
- Pravochol
- Amiodarone
- Neurotin
- Zoloft
- Vitamin E

97



98




99

Called Primary Care Physician to Discuss Findings


- ~ D/C amiodarone
- ~ Primary Care Physician switches patient to diltiazem

Class	Action	Drugs
I	Sodium channel blockade	Quinidine, Procainamide, Disopyramide, Lignocaine, Mexiletine, Tocainide, Flecainide, Propafenone
II	β -adrenergic blockade	Propranolol, Acebutolol, Carvedilol, Esmolol ...
III	Prolong repolarisation	Amiodarone, Bretylium, Sotalol, Difetilide, Azimilide
IV	Ca ²⁺ antagonism	Verapamil, Diltiazem, Semotiadil


100




101



102



103



104

Amiodarone Ocular Side Effects

- ~ Halos and colored lights, reported symptoms
- ~ Corneal opacities
 - * Epithelial basal cell layer
 - * Bilateral, dose and duration related
 - * Reversible
 - * Dot, Linear, cornea verticillata (whorl like pattern found later)
- ~ Conjunctiva, lens, retina and optic nerve deposits
- ~ Optic neuropathy has been reported
 - * Unilateral and bilateral cases

<http://www.optometry.co.uk/articles/20020517/patel20020517.pdf>

105


Cornea Verticillata (Whorls)

- ~ Drug-induced
 - * Amiodarone
 - * Chloroquine/hydroxychloroquine
 - * Tamoxifen
 - * Chlorpromazine
 - * Indomethacin


106

Another Patient Complaining of Blurry Vision Taking Amiodarone

107



108



109


Case 11

110


67-year-old man complains of vision slowly deteriorating over the past 8 months

- ≈ History of NA-ION 10 months ago OD
- ≈ Patient sees family physician for physical due to recent NA-ION
 - * Patient has not been to PCP for 35 years
 - * Patient started Cardarone
 - * VA 20/80 OD 20/25 OS (9 months ago)
- ≈ VA 20/400 OD 20/200 OS (today)
- ≈ CF: severe constriction OU
- ≈ SLE: vortex corneal whorls OU

111



112



113



114



115